Summit Therapeutics (SMMT) Q3 2025 earnings summary

Executive summary

• Ivonescimab plus chemotherapy demonstrated significant progression-free survival (PFS) benefit and improved response rates over tislelizumab plus chemotherapy in advanced squamous non-small cell lung cancer (NSCLC), with a hazard ratio of 0.60 (p<0.0001) and consistent benefit across PD-L1 subgroups.

• Tumor response rates and duration of response were higher and more durable for ivonescimab, with a median duration of response of 11.2 months and objective response rate of 75.6%.

• Safety profile of ivonescimab was manageable and comparable to control, with low rates of Grade 3+ bleeding and adverse events leading to discontinuation.

• Ongoing and planned global Phase III trials in NSCLC and colorectal cancer (CRC), including collaborations with major cancer centers and Revolution Medicines for RAS-mutant tumors.

• Expanded licensing agreement with Akeso covers additional territories, with milestone and royalty obligations.

Financial highlights

• Ended Q3 2025 with $238.6 million in cash and short-term investments, down from $412.3 million at year-end 2024.

• GAAP operating expenses for Q3 2025 were $234.2 million, up from $58.4 million year-over-year, mainly due to a $111.4 million increase in stock-based compensation.

• Non-GAAP operating expenses for Q3 2025 were $103.4 million, up from $39.0 million year-over-year, reflecting clinical study expansion.

• Net loss for Q3 2025 was $231.8 million ($0.31/share); non-GAAP net loss was $101.0 million ($0.13/share).

• Stock-based compensation expense surged to $130.8 million for Q3 2025 due to modifications to performance-based options.

Outlook and guidance

• Plans to submit a Biologics License Application (BLA) for ivonescimab in Q4 2025, with FDA approval contingent on demonstrating a statistically significant overall survival (OS) benefit.

• HARMONi-3 squamous NSCLC cohort enrollment expected to complete in H1 2026, with PFS analysis in H2 2026; non-squamous cohort to complete in H2 2026, with PFS analysis in H1 2027.

• HARMONi-GI3 trial in colorectal cancer to begin U.S. site activation by end of 2025, targeting 600 patients.

• Clinical trials with Revolution Medicines for RAS-mutant tumors to begin in early 2026.

• Expects continued operating losses and significant cash outflows as clinical development progresses; current cash is insufficient to fund operations for the next 12 months.